Generation Bio Beheer
Beheer criteriumcontroles 3/4
De CEO Generation Bio is Geoff McDonough, benoemd in Oct2017, heeft een ambtstermijn van 7.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.32M, bestaande uit 27.2% salaris en 72.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.76% van de aandelen van het bedrijf, ter waarde $ 3.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 6.9 jaar.
Belangrijke informatie
Geoff McDonough
Algemeen directeur
US$2.3m
Totale compensatie
| Percentage CEO-salaris | 27.2% |
| Dienstverband CEO | 7.1yrs |
| Eigendom CEO | 2.8% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 6.9yrs |
Recente managementupdates
Recent updates
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$158m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$2m | US$630k | -US$127m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$127m |
| Mar 31 2023 | n/a | n/a | -US$134m |
| Dec 31 2022 | US$4m | US$606k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$135m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$129m |
| Dec 31 2021 | US$6m | US$583k | -US$119m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$101m |
| Mar 31 2021 | n/a | n/a | -US$88m |
| Dec 31 2020 | US$2m | US$516k | -US$81m |
| Sep 30 2020 | n/a | n/a | -US$72m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$65m |
| Dec 31 2019 | US$593k | US$424k | -US$61m |
Compensatie versus markt: De totale vergoeding ($USD 2.32M ) Geoff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).
Compensatie versus inkomsten: De vergoeding van Geoff is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Geoff McDonough (54 yo)
7.1yrs
Tenure
US$2,315,263
Compensatie
Dr. Cameron Geoffrey McDonough, also known as Geoff, M.D. serves as Independent Director of Third Harmonic Bio, Inc. since March 2024. He had been an Independent Director of Surface Oncology, Inc. since Fe...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.1yrs | US$2.32m | 2.76% $ 4.0m | |
| Chief Financial Officer | 4.3yrs | US$1.14m | 0.086% $ 123.9k | |
| Chief Scientific Officer | 5.5yrs | US$1.15m | 0.37% $ 534.2k | |
| Chief Legal Officer & Secretary | 1.6yrs | US$1.21m | 0.021% $ 30.6k | |
| Co-Founder | 8.1yrs | geen gegevens | geen gegevens | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Chief Operating Officer | 2.8yrs | geen gegevens | 0.024% $ 34.7k | |
| Chief Human Resources Officer | 1.7yrs | geen gegevens | geen gegevens | |
| Chief Strategy Officer | 2.2yrs | geen gegevens | 0.18% $ 263.7k |
3.5yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.1yrs | US$2.32m | 2.76% $ 4.0m | |
| Independent Chairman | 7.1yrs | US$181.21k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$143.71k | 0.20% $ 283.9k | |
| Independent Director | 6.3yrs | US$151.21k | 0.80% $ 1.2m | |
| Independent Director | 6.9yrs | US$143.71k | 0.24% $ 348.5k | |
| Chairman of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 6.9yrs | US$143.71k | 0.32% $ 461.3k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.7yrs | US$144.21k | 0.014% $ 20.5k | |
| Independent Director | 6.9yrs | US$143.71k | 0.071% $ 102.6k | |
| Member of Scientific Advisory Board | 6.1yrs | geen gegevens | geen gegevens |
6.9yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).